Dr Cheryl Barton

Freelance Journalist

Dr Barton is a freelance journalist specializing in the pharma and biotech sector.

Refine Search

Latest from Dr Cheryl Barton

M&A activity – CRISPR fuelling investor interest in gene editing

A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024

Pharmaceutical

M&A activity – new inflammatory disease targets fuelling investment interest

A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024

Pharmaceutical

M&A activity – Fuelling innovation in hard-to-treat CNS disorders

An Analysis of M&A activity in the CNS space. 26 July 2024

Pharmaceutical

Steady ahead for Novartis following year of strategic investments

An analysis of the investment activity of Novartis in recent years. 5 April 2024

Pharmaceutical

Are GLP-1s finding the right balance in obesity?

An analysis of recent pharma activity in the metabolic diseases field and why obesity is a hot topic amongst investors. 8 March 2024

Pharmaceutical

Is hepatology a pharma graveyard or a promising blockbuster opportunity?

A feature analyzing recent pharma activity in the hepatology field and why NASH remains unchartered territory. 20 December 2023

Pharmaceutical

Pharma is focusing on the heart of the problem

A feature analyzing how - and why - cardiology is of renewed interest to pharma. 17 November 2023

Biosimilars

Biosimilars gaining traction in the USA

A feature on recent market activity in the biosimilar sector. 18 September 2023

Pharmaceutical

Biotech, pharma, and VCs invest in new technologies to drive future growth

A feature analyzing the recent investment activity in digital technologies and AI. 11 August 2023

Pharmaceutical

Acquisitions drive growth in pharma and biotech in the first half of 2023

An analysis of recent mergers and acquisitions in the pharma sector. 3 July 2023

Biotechnology

Innovative cell and gene technologies gaining investor attention

A feature analyzing recent investment activity in cell and gene therapies. 9 June 2023

Pharmaceutical

AbbVie M&A activity: is it enough to overcome Humira biosimilars?

A feature on the US drugmaker's drive to replace declining sales of the world's biggest-selling drug. 18 May 2023

Pharmaceutical

Asia-Pacific: is the time ripe for investment?

A Feature on recent investment activity in Asia-Pacific. 7 April 2023

Biotechnology

Antibody-drug conjugates taking center stage in oncology

An analysis of the recent investment activity in antibody–drug conjugates (ADCs) prior to Pfizer's newly-announced $43 billion takeover of Seagen. 13 March 2023

Biotechnology

Renewed interest in RNA-targeted therapies - delivery remains the achilles heel

An analysis of the recent progress in RNA therapeutics and future opportunities. 31 January 2023

Pharmaceutical

Pharma has set its sights on ophthalmology opportunities

An analysis of how - and why - ophthalmology is increasingly on pharma and investors' radar as a new growth area. 8 December 2022

Biotechnology

Immunology: investors are tapping into high growth specialty medicines

A Feature analyzing how - and why - immunology remains a steady area of investment for big pharma and private investors. 31 October 2022

Biotechnology

M&A activity in orphan and rare diseases

A Feature on the deals being done in a lively sub-sector of the pharmaceutical industry. 6 October 2022

Pharmaceutical

Spin-outs and demergers - generating shareholder value?

Pharma companies continue to evaluate novel ways to increase their return on investment and generate shareholder value, basic earnings per share (EPS), plus stock price. Historically, pharma has pursued mergers and acquisitions to undermine R&D and drive growth. 19 September 2022

Pharmaceutical

The fall and rise of M&A investment in neuroscience

A feature on renewed interest in an area where the difficulty for drugmakers is matched only by the potential rewards. 3 August 2022

12 Next page

Dr Cheryl Barton

Today's issue

Latest from Dr Cheryl Barton

Company Spotlight